Moderna’s Covid-19 vaccine was overwhelmingly successful at preventing serious infection in adolescents between the ages of 12 and 17, the company announced Tuesday, targeting early June to seek authorization for expanding use of the shot currently only available to adults.

A study of more than 3,700 adolescents found no cases of the coronavirus, based on the same definition for an infection as adult trials, among those who received both doses of Moderna’s vaccine. The company also tracked milder instances of Covid among adolescents in the study since younger age groups typically have lower incidence rates, and the vaccine had a 93 percent efficacy rate starting 14 days after the first dose based on that metric.

“We are encouraged that mRNA-1273 was highly effective at preventing Covid-19 in adolescents. It is particularly exciting to see that the Moderna vaccine can prevent infection,” Moderna CEO Stéphane Bancel said in a statement.

“We will submit these results to the FDA and regulators globally in early June and request authorization. We remain committed to doing our part to help end the pandemic.”

If Moderna secures federal authorization to offer its vaccine to adolescents, it would become the second option available to younger populations as the country presses forward toward widespread immunization.

The Centers for Disease Control earlier this month approved  deploying the Pfizer vaccine, originally permitted for residents 16 and up, in 12 to 15 year olds, a population numbering about 400,000 in Massachusetts.